4.7 Article

Humoral Response to SARS-CoV-2 Vaccine of a Patient Receiving Methotrexate Treatment and Implications for the Need of Monitoring

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Letter Rheumatology

SARS CoV-2 infection among patients using immunomodulatory therapies

Kevin L. Winthrop et al.

ANNALS OF THE RHEUMATIC DISEASES (2021)

Article Rheumatology

The effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: a cohort study

Satveer K. Mahil et al.

Summary: Patients receiving methotrexate may have impaired humoral immunity to a single dose of the BNT162b2 vaccine, but not those receiving targeted biologics. Cellular immune responses are preserved in all groups. Real-world pharmacovigilance studies are needed to determine the clinical effectiveness of these findings.

LANCET RHEUMATOLOGY (2021)

Editorial Material Rheumatology

Impact of methotrexate on first-dose COVID-19 mRNA vaccination Comment

Caoilfhionn M. Connolly et al.

LANCET RHEUMATOLOGY (2021)

Article Dermatology

Clinical outcomes of COVID-19 in patients taking tumor necrosis factor inhibitors or methotrexate: A multicenter research network study

Ahmed Yousaf et al.

Summary: This study suggests that patients with recent TNFi or methotrexate exposure do not have increased hospitalization or mortality compared with patients with COVID-19 without recent TNFi or methotrexate exposure.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2021)

Article Biochemistry & Molecular Biology

Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity

Wilfredo F. Garcia-Beltran et al.

Summary: New variants of SARS-CoV-2 show high resistance to vaccine neutralization, with some able to escape vaccine responses with just a few mutations, highlighting the importance of developing broadly protective measures against variants.
Review Immunology

Mini Review Immunological Consequences of Immunization With COVID-19 mRNA Vaccines: Preliminary Results

Andrea Lombardi et al.

Summary: BNT162b2 and mRNA-1273 vaccines can elicit specific antibodies and neutralizing antibodies levels higher than those observed in convalescent serum of COVID-19 patients within the first 100 days after vaccination, with a reassuring safety and efficacy profile. The vaccine-induced T cell response is oriented towards a beneficial T(H)1 response, without evidence of vaccine-enhanced disease reported.

FRONTIERS IN IMMUNOLOGY (2021)

Article Biochemistry & Molecular Biology

Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies

Delphine Planas et al.

Summary: The ability of convalescent sera from individuals with coronavirus disease 2019 and those vaccinated with BNT162b2 to neutralize SARS-CoV-2 variants B1.1.7 and B.1.351 decreases, but increases after two vaccine doses. The study found that the B.1.1.7 and B.1.351 variants may have acquired partial resistance to neutralizing antibodies generated by natural infection or vaccination, particularly in individuals with low antibody levels. This suggests that the B.1.351 variant may pose a greater risk of infection in immunized individuals.

NATURE MEDICINE (2021)

Article Rheumatology

Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study

Victoria Furer et al.

Summary: Vaccination with mRNA BNT162b2 vaccine showed reduced immunogenicity in patients with AIIRD compared to the general population, with risk factors including older age and treatment with glucocorticoids, rituximab, mycophenolate mofetil (MMF), and abatacept. However, most patients maintained stable disease activity post-vaccination.

ANNALS OF THE RHEUMATIC DISEASES (2021)

Article Rheumatology

Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease

Rebecca H. Haberman et al.

Summary: The study found that patients with immune-mediated inflammatory diseases (IMIDs) on methotrexate treatment showed impaired humoral and cellular immune response to COVID-19 mRNA vaccines, while healthy subjects and IMID patients on biologic treatments demonstrated strong antibody responses. These results suggest that different strategies may need to be explored to enhance immunization efficacy for IMID patients on methotrexate treatment.

ANNALS OF THE RHEUMATIC DISEASES (2021)

Article Multidisciplinary Sciences

SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses

Jackson S. Turner et al.

Summary: SARS-CoV-2 mRNA vaccines induce a persistent germinal centre B cell response in humans, leading to the generation of robust humoral immunity, especially more significant in individuals previously infected with the virus.

NATURE (2021)

Article Virology

Neutralizing Antibodies in COVID-19 Patients and Vaccine Recipients after Two Doses of BNT162b2

Julien Favresse et al.

Summary: Assessing and comparing neutralizing antibodies in COVID-19 patients and vaccinated individuals revealed stronger responses in moderate-severe patients compared to mild patients, while vaccinated individuals had significantly higher NAbs levels than patients.

VIRUSES-BASEL (2021)

Letter Rheumatology

COVID-19 in a patient with systemic sclerosis treated with tocilizumab for SSc-ILD

Carina Mihai et al.

ANNALS OF THE RHEUMATIC DISEASES (2020)